To the Editor: Previous research suggests that hormonal factors might influence the development of keratinocyte cancers (KCs), but the evidence is inconsistent.
1,2 A potential mechanism for the association is photosensitization with use of estrogen, a hormone included in menopausal hormone therapy (MHT). 3 We examined the association between hormonal and reproductive factors and subsequent risk for first histologically confirmed primary basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) in a large cohort of women that was well-characterized with respect to important potential confounding factors, as well as clinical factors that might inform about possible detection bias.
White women from the QSkin Sun and Health Study 4 with no history of melanoma, excisions for skin cancer, or [5 self-reported ablations for sunspots or skin cancers (n ¼ 11,152) were eligible for the study. The latter criterion was stipulated to minimize potential bias caused by including women with prior disease in the analyses, considering that KCs can be ablated without a histologically confirmed diagnosis. Information on hormonal and reproductive factors was self-reported at baseline (2011). KC outcomes were identified from the administrative medical claims data (Medicare, Australia's universal health insurance scheme) until June 30, 2014, and exact diagnoses of BCC and SCC were determined through linked pathology records. 5 We used Cox proportional hazards models to estimate the hazard ratios (HRs) associated with oral contraceptives (OCs) and MHT, age at menarche, menopausal status, age at menopause and parity, and first histologically confirmed BCC or SCC while taking into account the effects of age, sun exposure, and phenotypic and lifestyle characteristics.
Selected characteristics of the study cohort, overall and amongst postmenopausal women stratified by MHT use, are provided in Supplemental Table I (available at http://www.jaad.org). During a median follow-up of 3 years, 336 women developed $1 BCCs (mean age 55.0 years) and 85 women, $1 SCCs (mean age 55.6 years). We found no association between incidence of BCC or SCC and OC use (ever or never, duration), parity, or age at menarche or menopause (Tables I and II) . Among postmenopausal women, ever (vs never) use of MHT at baseline was associated with an increased risk for BCC (adjusted HR 1.46; 95% confidence interval 1.07-1.97), but there was no dose response with duration of use (P trend ¼ .2; Table I ). MHT use was not associated with SCC (adjusted HR 0.79; 95% confidence interval 0.45-1.38). We investigated detection bias as a possible explanation for the positive association between MHT use and BCC through analyses stratified by self-reported history of skin checks by a doctor and number of Medicare claims for doctor consultations, biopsies, and cryotherapy treatments during follow-up; we observed no material difference in the effect estimates according to these factors. The association between MHT use and BCC did not differ materially across strata of sun exposure variables (data not shown).
Our findings in relation to both OC and MHT use and risk for BCC accord with findings from 2 other prospective studies, the US Radiologic Technologists Study 1 and the Danish Diet, Cancer, and Health cohort, 2 although a significant trend with duration of MHT use was observed in the US Radiologic Technologists Study cohort. 1 Limitations of our study was the relatively short follow-up and constrained sample size that limited analyses for SCC.
In summary, we did not observe an association between OC use or reproductive factors and incidence of BCC or SCC, but we did find a modest positive association between ever use of MHT and BCC only. Although we found no conclusive evidence of detection bias or confounding to explain the latter finding, in view of the lack of a dose-response relationship, we counsel cautious interpretation until further longitudinal studies have explored these associations. y Age at menarche adjusted for age at baseline, skin phototype (tanning), freckling on face at age 21, moles at age 21, skin checks by a doctor in the past 3 years, and smoking status. z P trend is based on the continuous variable.
x Parity adjusted for age at baseline, skin color, freckling on face at age 21, moles at age 21, and smoking status. jj Menopausal status at baseline adjusted for age at baseline, skin color, freckling on face at age 21, moles at age 21, skin checks by a doctor in the past 3 years, and smoking status. { Age at menopause adjusted for age at baseline, skin phototype (tanning) and moles at age 21, skin checks by a doctor in the past 3 years, and smoking status. # OC use adjusted for age at baseline, skin color, freckling on face at age 21, moles at age 21, number of sunburns as a child, skin checks by a doctor in the past 3 years, and smoking status. **MHT use adjusted for age at baseline, eye color, moles at age 21, sunburns as a teenager/youth, skin checks by a doctor in the past 3 years, and smoking status. CI, Confidence interval; HR, hazard ratio; MHT, menopausal hormone therapy; Ref, reference; SCC, squamous cell carcinoma. *Numbers might not sum to total due to missing data. y Age at menarche adjusted for age at baseline, skin phototype (tanning), freckling on face at age 21, moles at age 21, and smoking status. z P trend is based on the continuous variable.
x Parity adjusted for age at baseline, skin color, freckling on face at age 21, moles at age 21, and smoking status. jj Menopausal status at baseline adjusted for age at baseline, skin color, freckling on face at age 21, moles at age 21, and smoking status. { Age at menopause adjusted for age at baseline, skin phototype (tanning) and moles at age 21, and smoking status. # OC use adjusted for age at baseline, skin color, freckling on face at age 21, moles at age 21, number of sunburns as a child, and smoking status. **MHT use adjusted for age at baseline, eye color, moles at age 21, sunburns as a teenager/youth, and smoking status.
Forehead horizontal primary closure: A retrospective analysis of 25 cases assessing for long-term eyebrow asymmetry
To the Editor: Horizontal primary closure of forehead defects is straightforward and allows for lower wound edge tension with the ability to hide the scar in the horizontal relaxed skin tension lines. [1] [2] [3] [4] [5] However, for forehead defects near the eyebrow this technique is often abandoned over concern for longterm upward tension on the eyebrow. [1] [2] [3] [4] [5] Instead, more complex and riskier flaps and grafts are used to avoid this risk. [1] [2] [3] [4] [5] This study aimed to measure the long-term differences in eyebrow heights in patients with horizontal forehead closures.
Using our institution's photo database, we evaluated 25 patients who had paramedian and laterally based horizontal primary forehead closures following Mohs surgery during 2012-2015. Closures were $1 cm above the eyebrow, 1 cm beneath the hairline, and resulted in noticeable elevation of the eyebrow. There was minimal-to-no undermining and no periosteal anchoring sutures. A front-facing image and software were used to measure the defects and closures. These patients then had a follow-up visit 3-36 months after surgery to measure the distances between their lateral canthus and lateral-upper eyebrow, midpupillary line to mid-upper eyebrow, and medial canthus to medial-upper eyebrow. Both eyebrows were measured and the differences between calculated. Numbness, paresthesia, difficulty closing the eye, and the patient's personal perception of eyebrow asymmetry was noted at follow-up. Twenty-five age-and sex-matched controls without previous surgery to the forehead were selected from our photo database and had their eyebrow heights measured in a similar fashion.
Mean eyebrow height asymmetry was not significantly different between patients with forehead surgery and the control group (Table I ). This finding highlights that eyebrows are not always symmetric at baseline among individuals in the general population. 5 Among 5 patients who were measured 3-6 months after closure, the accumulated mean difference of the 3 height measurements was 3.0 mm, but among 6 patients measured after 31 months, the difference was only 0.2 mm. Three of 25 patients (12%) noted numbness of their forehead ipsilateral to the surgery site. A staff observer noted visible asymmetry with 5 of 25 (20%) patients; only 3 of these patients had noticed the difference themselves. Three patients had visible asymmetry [6 months later (ie, at 8, 15, and 17 months). Only 1 of these patients noticed the difference themselves (8 months after the operation). No patient (n ¼ 10) measured after 18 months had a visible difference. Fig  1 reveals a patient' s gradual correction of eyebrow asymmetry over time.
Horizontal primary forehead closures might initially cause eyebrow asymmetry; however, our long-term follow-up showed no significant differences in eyebrow heights with little chance of longterm complications. Gravitational forces, compounded by the action of depressor muscles, and the inherent laxity of older skin are believed to contribute to this correction. 4 Previous authors have stated that horizontal primary closures resulting in eyebrow elevations up to 1 cm have the ability to realign over time. [2] [3] [4] Although our investigation is limited by a small sample size and the method of one-time measurement, horizontal primary closures might not cause problems for patients with forehead defects near the eyebrows. Further investigations evaluating this more ideal closure technique for this population should be conducted. MHT, Menopausal hormone therapy; SD, standard deviation; Q, quartile. *Numbers might not sum to total due to missing data. MHT use missing for n ¼ 123 women. y P value for significant difference between MHT users and nonusers using the Ryan-Einot-Gabriel-Welsch multiple range test.
